Year-End newsletter

| USA, News

Dear Partners, Friends and Followers,

2018 has been an exciting and very successful year for Immatics!

We would like to thank you for your support, your companionship and dedication. Together we achieved significant progress in developing safe and effective T-cell redirecting immunotherapies both in our proprietary and partnered pipeline.

We wish to share key highlights and accomplishments with you in our Year-End newsletter. You can download it here.

Happy Holidays and a healthy and fresh start into the New Year 2019.

The Immatics-Team

Press Contact

Dr Nikola Wiegeler

Press contact,
Immatics Biotechnologies GmbH

+49 7071 5397-0

Go back